戊聚糖多硫酸钠与视网膜疾病之间的关联
该研究利用美国FDA不良事件报告系统(2013年1月至2020年6月)进行比例失衡分析,比较戊聚糖多硫酸钠(PPS)与其他间质性膀胱炎/膀胱疼痛药物的视网膜不良事件报告。PPS组任何黄斑事件的报告比例升高(PRR 1.21,95%CI 1.01-1.44),黄斑变性、黄斑病、视网膜营养不良、视网膜损伤和视网膜毒性报告比例均更高。结论认为PPS使用与黄斑病风险增加相关。
要点
- PPS组任何黄斑事件报告比例高于其他膀胱药物组(PRR 1.21,95%CI 1.01-1.44)。
- PPS组黄斑病报告83例(3.4%)vs 其他药物组2例(0.03%)。
- PPS组黄斑变性20例(0.8%)vs 其他药物组15例(0.2%)。
核心结论
- 研究结果进一步支持PPS使用与黄斑病风险增加相关。
- 作者认为,在开始PPS治疗前排除已有视网膜异常的研究将强化现有证据。
研究设计与样本
- 采用比例失衡分析,数据来自美国FDA不良事件报告系统2013年1月至2020年6月。
- PPS组纳入2775份报告(女性1966份,70.9%),其他药物组纳入6833份报告(女性4036份,59.1%)。
- 其他药物组为用于间质性膀胱炎、膀胱炎、膀胱疾病或膀胱疼痛的药物报告。
主要发现
- PPS组任何黄斑事件相对所有其他事件的报告比例高于其他间质性膀胱炎和膀胱疼痛药物组(PRR 1.21,95%CI 1.01-1.44)。
- 黄斑变性报告比例PPS组20例(0.8%)vs 其他药物组15例(0.2%)。
- 黄斑病报告比例PPS组83例(3.4%)vs 其他药物组2例(0.03%)。
- 视网膜营养不良报告比例PPS组3例(0.1%)vs 其他药物组0例。
- 视网膜损伤报告比例PPS组5例(0.2%)vs 其他药物组0例;视网膜毒性报告比例PPS组3例(0.1%)vs 其他药物组0例。
关键数值与推荐
- 视网膜不良事件通过视网膜疾病MedDRA标准化查询识别,该查询包括因血供阻断、营养缺乏、毒素及影响视网膜的疾病所致的视网膜损伤相关情况。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Case series have identified a macular condition hypothesized to be associated with the use of pentosan polysulfate sodium (PPS). Observational studies seeking to quantify this association have yielded equivocal results. OBJECTIVE: To estimate the association between PPS exposure and maculopathy. DESIGN, SETTING, AND PARTICIPANTS: This disproportionality analysis was conducted using the US Food and Drug Administration Adverse Event Reporting System from January 2013 through June 2020. EXPOSURE: Adverse event reports for pentosan polysulfate were selected and compared with adverse event reports associated with drugs taken for the following indications: interstitial cystitis, cystitis, bladder disorder, or bladder pain. MAIN OUTCOME MEASURES: Retinal adverse events were identified using the retinal disorders Standardized Medical Dictionary for Regulatory Activities (MedDRA) Query, which includes conditions associated with retinal damage attributable to blockage of its blood supply, nutritional deficiencies, toxins, and diseases affecting the retina. RESULTS: There were 2775 reports available for analysis in the PPS group (of which 1966 were for women [70.9%]) and 6833 reports in the other drugs group (of which 4036 [59.1%] were for women). The proportion of adverse events for any macular event relative to all other events was elevated for the users of PPS compared with those using other interstitial cystitis and bladder pain drugs (proportionate reporting ratio [PRR], 1.21 [95% CI, 1.01-1.44]). With respect to specific retinal conditions, macular degeneration (20 [0.8%] vs 15 [0.2%]), maculopathy (83 [3.4%] vs 2 [0.03%]), retinal dystrophy (3 [0.1%] vs 0), retinal injury (5 [0.2%] vs 0), and retinal toxicity (3 [0.1%] vs 0) were proportionately more common among users of PPS compared with those using other interstitial cystitis and bladder pain drugs, respectively. CONCLUSIONS AND RELEVANCE: The results of the current study add to the growing evidence that PPS use is associated with an increased risk of maculopathy. Studies that rule out prevalent retinal abnormalities prior to the initiation of PPS would strengthen the current body of literature.
引用
- McGwin G, MacLennan P, Owsley C, et al. Association Between Pentosan Polysulfate Sodium and Retinal Disorders. JAMA Ophthalmol. 2022. PMID: 34792558. doi:10.1001/jamaophthalmol.2021.4778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。